NIKKEI 225
38,277.73 +725.57 (+1.93%) HANG SENG
16,828.93 +317.24 (+1.92%) CRUDE OIL
83.46 +0.10 (+0.12%) GOLD FUTURES
2,335.40 -6.70 (-0.29%) DOW
38,503.69 +263.71 (+0.69%) Bitcoin GBP
53,518.89 -261.55 (-0.49%)
Cellectis S.A. (CLLS)
After hours:
| Previous close | 2.6400 |
| Open | 2.4600 |
| Bid | 0.0000 x 0 |
| Ask | 4.7500 x 50000 |
| Day's range | 2.4600 - 2.6497 |
| 52-week range | 0.9630 - 3.7740 |
| Volume | |
| Avg. volume | 37,838 |
| Market cap | 188.497M |
| Beta (5Y monthly) | 3.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.43 |
GlobeNewswireCellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseasesNon-viral circular ssDNA delivery associated to TALEN® gene editing allows high levels of gene insertion in long-term repopulating HSPCs NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will pres
- GlobeNewswire
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that TALEN-mediated intron editing of hematopoietic stem and progenitor cells (HSPCs) enables transgene expression restricted to the myeloid lineage. This approach co
- GlobeNewswire
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preliminary data exploring novel TALEN® editing process in hematopoietic stem and progenitor cells (HSPCs) will be presented at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, to be held in Baltimore, Maryland,
